Dr. Santanu Dutta, Sanchita Das, Sumanta Ghosh, Dr. Shilpa Basu Roy


Purpose: To evaluate the efficacy and safety of oral tadalafil in reducing pulmonary arterial hypertension (PAH) in adult ostium secundum strial septal defect (OS-ASD) patients.

Methods: Pre-operative patients with OSD complicated with PAH, age >18 years, were enrolled into two groups; Group A (oral tadalafil) and Group B (without tadalafil) for over a period of 3 months. Pulmonary artery pressure (PAP) at baseline and post three month of treatment was measured to evaluate the efficacy of tadalafil. Independent t-test and p-value were used to compare the various parameters between two groups. Safety was assessed as the incidence of adverse events (AEs) during the three month treatment period.

Results: A statistically significant reduction in PAP from baseline was observed after completion of 3 months in patients receiving tadalafil (p=0.0004). On the contrary, an increase in PAP was observed in Group B patients not receiving tadalafil (from 41.86 ± 6.42 to 44.86 ± 5.33). Additionally, after three months of treatment, PAP between the two treatment groups was also statistically significant (p= 0.0006). No adverse events were associated with the use of oral tadafil.

Conclusion: Oral tadalafil reduced pulmonary artery pressure in adult OS-ASD with PAH patients.

Full Text:



Oster ME, Lee KA, Honein MA, Riehle-Colarusso T, Shin M, Correa A. Temporal trends in survival among infants with critical congenital heart defects. Pediatrics. 2013;131:e1502-8. doi: 10.1542/peds.2012-3435.

Chen FL, Hsiung MC, Hsieh KS, Li YC, Chou MC. Real time three-dimensional transthoracic echocardiography for guiding Amplatzer septal occluder device deployment in patients with atrial septal defect. Echocardiography. 2006;23:763-70.

Nashat H, Montanaro C, Li W, Kempny A, Wort SJ, Dimopoulos K, Gatzoulis MA, Babu-Narayan SV. Atrial septal defects and pulmonary arterial hypertension. J Thorac Dis. 2018 ;10 (Suppl 24):S2953-S2965. doi: 10.21037/jtd.2018.08.92.

Nassif M, Heuschen CB, Lu H, Bouma BJ, van Steenwijk RP, Sterk PJ, Mulder BJ, de Winter RJ. Relationship between atrial septal defects and asthma-like dyspnoea: the impact of transcatheter closure. Neth Heart J. 2016; 24:640-646.

Giaid A, Saleh D. Reduced expression of endothelial nitric oxide syn¬thase in the lungs of patients with pulmonary hypertension. N Engl J Med. 1995;333:214–221.

Li L, Jick S, Breitenstein S, Hernandez G, Michel A, Vizcaya D. Pulmonary arterial hypertension in the USA: an epidemiological study in a large insured pediatric population. Pulm Circ. 2017;7:126–36.

Marelli AJ, Ionescu-Ittu R, Mackie AS, Guo L, Dendukuri N, Kaouache M. Lifetime prevalence of congenital heart disease in the general population from 2000 to 2010. Circulation. 2014;130:749–56.

Galie N Hoeper MM, Humbert M,Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J.2009,34:1219-63

Jean-LUC Vachiery, Sandrine Huez, Hunter Gillies, Gary Layton, Naoto Hayashi, Xiang Gao and Robert Naeije. Safety, tolerability and pharmacokinetics of an intravenous bolus of sildenafil in patients with pulmonary arterial hypertension.

Fathallah M, Krasuski RA. Multifaceted Approach to Pulmonary Hypertension in Adults With Congenital Heart Disease. Prog Cardiovasc Dis. 2018; 61: 320-327. doi: 10.1016/j.pcad.2018.07.017.

Giaid A, Saleh D. Reduced expression of endothelial nitric oxide syn¬thase in the lungs of patients with pulmonary hypertension. N Engl J Med. 1995;333:214–221.

Galiè N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, Shapiro S, White RJ, Chan M, Beardsworth A, Frumkin L, Barst RJ; Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009; 119: 2894-903. doi: 10.1161/CIRCULATIONAHA.108.839274.

Archer SL, Huang JM, Hampl V, Nelson DP, Shultz PJ, Weir EK. Nitric oxide and cGMP cause vasorelaxation by activation of a charybdotoxin-sensitive K channel by cGMP-dependent protein kinase. Proc Natl Acad Sci U S A. 1994;91:7583–7587.

Corbin JD, Beasley A, Blount MA, Francis SH. High lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitors. Biochem Biophys Res Commun. 2005;334:930–938.

Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev. 1995;75:725–748.

Henrie AM, Nawarskas JJ, Anderson JR. Clinical utility of tadalafil in the treatment of pulmonary arterial hypertension: an evidence-based review. Core Evid. 2015 Nov 2;10:99-109. doi: 10.2147/CE.S58457. eCollection 2015.

Yamazaki H, Kobayashi N, Taketsuna M, Tajima K, Suzuki N, Murakami M. Safety and effectiveness of tadalafil in pediatric patients with pulmonary arterial hypertension: a sub-group analysis based on Japan post-marketing surveillance. Curr Med Res Opin. 2017; 33: 2241-2249. doi: 10.1080/03007995.2017.1354832.

Maki S, Tanaka H, Tsuji M, Furuhashi F, Magawa S, Kaneda MK, Nii M, Tanaka K, Kondo E, Tamaru S, Ogura T, Nishimura Y, Endoh M, Kimura T, Kotani T, Sekizawa A, Ikeda T. Safety Evaluation of Tadalafil Treatment for Fetuses with Early-Onset Growth Restriction (TADAFER): Results from the Phase II Trial. J Clin Med. 2019; 8. pii: E856. doi: 10.3390/jcm8060856.


  • There are currently no refbacks.